Both are semaglutide, a GLP-1 receptor agonist that reduces appetite and slows stomach emptying, licensed for weight management alongside a reduced-calorie diet and increased physical activity. Both need a dose-escalation period to manage tolerability. Both carry the same core safety warnings, including the contraindication in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both need a prescriber's ongoing review.
Neither is a quick fix, and neither replaces lifestyle change. They make it more achievable.
The injection delivers semaglutide directly under the skin, reaching the bloodstream at roughly 89% of the dose given. The tablet has to survive the stomach first. It is co-formulated with an absorption enhancer, SNAC, that briefly makes a small patch of stomach lining more permeable while the tablet dissolves against it.
Even done correctly, only around 1% of the dose in each tablet reaches the bloodstream. That is why the tablet is dosed far higher than the injection, 25 mg against 2.4 mg, and why it comes with a strict administration routine the injection simply does not need.
There is no head-to-head trial of oral Wegovy against the injection, so what follows is a comparison of separate trial results, not a direct contest. On these figures the tablet sits close to the standard 2.4 mg injection, above the first competing oral pill, and behind the higher-dose injectable pens and tirzepatide. Treat every figure as a trial average, not an individual prediction.
| Product | Trial | Mean weight loss |
|---|---|---|
| Oral Wegovy 25 mg tablet, once daily | OASIS 4, 64 weeks | ~16.6% (13.6% including people who stopped early) |
| Wegovy 2.4 mg injection, weekly | STEP 1, 68 weeks | ~14.9% |
| Wegovy 7.2 mg injection, high dose, weekly | STEP UP | ~20.7% |
| Orforglipron, non-peptide oral pill | ATTAIN-1, 72 weeks | ~11.2% |
| Tirzepatide, weekly injection | SURMOUNT-1, 72 weeks | up to ~20.9% |
Figures are mean weight loss from the main analysis of each trial. Different trials used different populations, durations and analysis methods, so the numbers are not directly comparable to each other.
The manufacturer has also published its own indirect comparison, ORION, claiming an advantage for oral semaglutide over orforglipron. As a sponsor-run indirect analysis without a real head-to-head trial, it is worth reading with that caveat attached.
Both forms share the same leading side effect: gastrointestinal upset. Around 74% of people on the oral 25 mg dose had a gastrointestinal adverse event in OASIS 4, against 42% on placebo. Overall treatment discontinuation for side effects was similar too, at roughly 7% against 6%, the same order of magnitude as the injection.
Switching form does not meaningfully change how likely you are to feel sick. Both work the same way in the gut.
The two formulations ask something quite different of your day, and this is usually what actually decides which one someone prefers.
- Frequency. Injection: once a week, same day each week. Tablet: every single day, with no day off.
- Storage and travel. The injection pen needs refrigeration until first use and then a limited time at room temperature, which matters for holidays and flights. The tablet needs no fridge, which is genuinely useful if you travel or live somewhere with less predictable access to cold storage.
- The routine. The injection is a five-second jab once a week, with no timing rules around food. The tablet has to be taken first thing, on an empty stomach, with no more than about half a glass of plain water, then a 30-minute wait before food, drink or other tablets, every morning. See how to take oral Wegovy for why each step matters.
- Needles. The single biggest reason people choose the tablet is avoiding injections. If needle aversion has stopped you starting treatment before, the tablet removes that barrier entirely.
- Forgiveness of an off day. Semaglutide's roughly one-week half-life means a single poorly-timed tablet is diluted into an existing reservoir and barely registers on its own. A missed weekly injection is a bigger single event, but happens far less often by design. Neither medicine forgives a repeated pattern of errors.
People who dislike or fear injections, travel often, or want to avoid fridge logistics tend to prefer the tablet. People who find a daily fasting-and-waiting routine hard to stick to, or who would rather have one predictable weekly moment than a daily one, tend to prefer the injection.
Some people switch between the two over time under medical supervision. That is a decision for you and your prescriber, not something to self-manage, because it involves specific dose-equivalence and timing judgements.
Oral Wegovy is not yet dispensed anywhere in Spain, and EU authorisation alone does not set that date. On 15 July 2026 the European Commission granted centralised marketing authorisation for oral Wegovy across all EU member states, the first oral GLP-1 medicine approved for weight management in the EU, following a positive opinion from the European Medicines Agency in May 2026. Centralised authorisation means the medicine is legally approved for the whole EU at once, but it does not put a box on a Spanish pharmacy shelf by itself.
Two things still have to happen nationally. Spain needs its own ficha técnica, the Spanish-language product information used by prescribers and pharmacists, and separately a pricing notification for the Spanish market, a step that applies even to a medicine that is not publicly funded. Once those are settled, the manufacturer still has to allocate supply to Spain and get stock into wholesalers and pharmacies.
It is worth calibrating expectations against how long this took for the injectable version of the same medicine: the EU authorised injectable Wegovy on 6 January 2022, and it did not reach Spanish pharmacies until May 2024, a gap of roughly 28 months. The manufacturer has said only that it is committed to bringing the tablet to more countries in the second half of 2026, having already launched it in the United States, the United Kingdom and the United Arab Emirates. That statement is not Spain-specific and is not a date. As of late August 2026, no Spanish launch date has been announced. The injectable pen remains available in Spain by private prescription since May 2024, at full private cost, because it is not funded by the Spanish national health system for weight management. Check the AEMPS CIMA medicines database for the current authorised status of any product before assuming availability.
The Holiday Doctor provides continuation prescriptions in Spain: an asynchronous clinical review, by a Spanish-registered English-speaking doctor, for adults already taking a regular medicine who need it bridged or repeated while they are in Spain.
- Prescribing or supplying oral Wegovy, which is not available in Spain
- Starting any weight-management medicine for the first time
- Advising on whether the tablet or the injection is right for you
- Arranging or supervising a switch between the two formulations
That kind of assessment belongs with a dedicated weight-management service such as Nivelta, our sister service, also from Doctor Abbs SL. If you already take a different regular medicine and need it continued while you are in Spain, that is exactly what we do.